Bio-Techne Launches Leo System for Efficient Protein Analysis
Bio-Techne Introduces Leo: A Breakthrough in Protein Analysis
Bio-Techne Corporation (NASDAQ: TECH) has commenced the distribution of its innovative Leo™ System, a significant evolution in high-throughput protein analysis powered by Simple Western™ Technology. This new system represents a substantial leap forward from previous Simple Western platforms, enhancing both sample throughput and reproducibility in protein detection and quantification. The Leo system provides the automation and precision that researchers need to perform protein assays efficiently.
Enhanced Features of the Leo System
The Leo system allows researchers to process as many as 100 samples simultaneously in a single run that lasts three hours. This capability translates to a staggering fourfold increase in throughput compared to the Jess™ Simple Western System and offers five times the speed of Sally Sue™ and Peggy Sue™ systems. With its advanced technology, Leo is designed to deliver high-quality, analytical grade protein quantitation essential for regulatory submissions.
Advanced Software Integration
One of the standout features of the Leo system is its sophisticated Compass for Simple Western Software. This upgraded software includes advanced analytical capabilities that enhance the user experience and ensure compliance with important regulations like 21 CFR Part 11, critical for laboratories worldwide.
Feedback from Early Users
Initial users of the Leo system have expressed tremendous satisfaction, highlighting its robust performance and the quality of data it generates. Beta testers noted that Leo's capabilities extend across various applications, including targeted protein degradation studies, clinical biomarker analyses, gene therapy potency tests, and numerous quality control applications. Such versatility showcases Leo's potential impact in both academic research and commercial development.
Accelerating Scientific Research
Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasized the system's role in expediting research. He stated, "With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators, and instruments. This advancement allows our customers to propel their innovative science forward and expedite the delivery of next-generation therapies to the market."
Future Perspectives and Webinars
The company plans to share extensive data on Leo's performance in an upcoming webinar, an opportunity for interested parties to understand the system's impact better. This event will serve as a platform for researchers to gain insights and ask questions regarding the applications and benefits of Leo in their work.
Contact and Company Information
Bio-Techne Corporation, operating under NASDAQ: TECH, continues to push boundaries in the field of protein analysis technology. The company is dedicated to providing superior solutions that improve research outcomes in various sectors. For more information, interested individuals can reach out to David Clair, Vice President of Investor Relations & Corporate Development, at 612-656-4416.
Frequently Asked Questions
What is the Leo System?
The Leo System is a high-throughput protein analysis system developed by Bio-Techne using Simple Western Technology, designed for improved sample processing and data accuracy.
How many samples can the Leo System process at once?
Leo allows simultaneous processing of up to 100 samples in just a three-hour run, significantly enhancing throughput and efficiency.
What are its compliance capabilities?
Leo includes the enhanced Compass for Simple Western Software, which supports 21 CFR Part 11 compliance, essential for regulated laboratory environments.
What feedback have early users provided?
Early users have praised Leo for its robust performance, reliable data quality, and versatility across a range of applications in protein research.
Who can I contact for more information?
For inquiries, you can contact David Clair, Vice President of Investor Relations & Corporate Development at Bio-Techne Corporation, via phone at 612-656-4416.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
